536 related articles for article (PubMed ID: 30854960)
1. Pathological Role of Advanced Glycation End Products (AGEs) and their Receptor Axis in Atrial Fibrillation.
Yamagishi SI; Sotokawauchi A; Matsui T
Mini Rev Med Chem; 2019; 19(13):1040-1048. PubMed ID: 30854960
[TBL] [Abstract][Full Text] [Related]
2. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications.
Yamagishi S; Fukami K; Matsui T
Cardiovasc Diabetol; 2015 Jan; 14():2. PubMed ID: 25582643
[TBL] [Abstract][Full Text] [Related]
3. Implication of advanced glycation end products (Ages) and their receptor (Rage) on myocardial contractile and mitochondrial functions.
Neviere R; Yu Y; Wang L; Tessier F; Boulanger E
Glycoconj J; 2016 Aug; 33(4):607-17. PubMed ID: 27277623
[TBL] [Abstract][Full Text] [Related]
4. Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.
Yamagishi S; Nakamura N; Suematsu M; Kaseda K; Matsui T
Mol Med; 2015 Oct; 21 Suppl 1(Suppl 1):S32-40. PubMed ID: 26605646
[TBL] [Abstract][Full Text] [Related]
5. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders.
Yamagishi S; Taguchi K; Fukami K
Glycoconj J; 2016 Aug; 33(4):683-90. PubMed ID: 27338620
[TBL] [Abstract][Full Text] [Related]
6. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System.
Yamagishi SI; Matsui T; Ishibashi Y; Isami F; Abe Y; Sakaguchi T; Higashimoto Y
Curr Pharm Des; 2017; 23(8):1135-1141. PubMed ID: 27774900
[TBL] [Abstract][Full Text] [Related]
7. Advanced glycation end products (AGEs) and their involvement in liver disease.
Hyogo H; Yamagishi S
Curr Pharm Des; 2008; 14(10):969-72. PubMed ID: 18473847
[TBL] [Abstract][Full Text] [Related]
8. Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; Overview of clinical evidence and potential contributions to disease.
Reynaert NL; Gopal P; Rutten EPA; Wouters EFM; Schalkwijk CG
Int J Biochem Cell Biol; 2016 Dec; 81(Pt B):403-418. PubMed ID: 27373680
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Interventions for Advanced Glycation-End Products and its Receptor- Mediated Cardiovascular Disease.
Prasad K; Tiwari S
Curr Pharm Des; 2017; 23(6):937-943. PubMed ID: 27719648
[TBL] [Abstract][Full Text] [Related]
10. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives.
Khalid M; Petroianu G; Adem A
Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454131
[TBL] [Abstract][Full Text] [Related]
11. Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.
Yamagishi S
Curr Drug Targets; 2011 Dec; 12(14):2096-102. PubMed ID: 22023404
[TBL] [Abstract][Full Text] [Related]
12. Role of Advanced Glycation Endproduct (AGE)-Receptor for Advanced Glycation Endproduct (RAGE) Axis in Cardiovascular Disease and Its Therapeutic Intervention.
Yamagishi SI
Circ J; 2019 Aug; 83(9):1822-1828. PubMed ID: 31366777
[TBL] [Abstract][Full Text] [Related]
13. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
14. A Glycation Angle to Look into the Diabetic Vasculopathy: Cause and Cure.
Ahmad S; Siddiqui Z; Rehman S; Khan MY; Khan H; Khanum S; Alouffi S; Saeed M
Curr Vasc Pharmacol; 2017; 15(4):352-364. PubMed ID: 28356033
[TBL] [Abstract][Full Text] [Related]
15. Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions.
Sharma AK; Sharma VR; Gupta GK; Ashraf GM; Kamal MA
Curr Drug Metab; 2019; 20(1):65-71. PubMed ID: 30207227
[TBL] [Abstract][Full Text] [Related]
16. Assay for advanced glycation end products generating intracellular oxidative stress through binding to its receptor.
Kobori T; Ganesh D; Kumano-Kuramochi M; Torigoe K; Machida S
Anal Biochem; 2020 Dec; 611():114018. PubMed ID: 33186591
[TBL] [Abstract][Full Text] [Related]
17. Kinetics, role and therapeutic implications of endogenous soluble form of receptor for advanced glycation end products (sRAGE) in diabetes.
Yamagishi S; Matsui T; Nakamura K
Curr Drug Targets; 2007 Oct; 8(10):1138-43. PubMed ID: 17979674
[TBL] [Abstract][Full Text] [Related]
18. Evidence for a role of advanced glycation end products in atrial fibrillation.
Raposeiras-Roubín S; Rodiño-Janeiro BK; Grigorian-Shamagian L; Seoane-Blanco A; Moure-González M; Varela-Román A; Álvarez E; González-Juanatey JR
Int J Cardiol; 2012 Jun; 157(3):397-402. PubMed ID: 21652096
[TBL] [Abstract][Full Text] [Related]
19. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications.
Yamagishi SI; Matsui T
Curr Pharm Des; 2018; 24(24):2802-2809. PubMed ID: 30156152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
